Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “B Cell ALL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00251394
What this trial is testing

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Dana-Farber Cancer Institute 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05057494
What this trial is testing

Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
AstraZeneca 607
Testing effectiveness (Phase 2)Study completedNCT00738829
What this trial is testing

Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-Cell
Arbeitsgemeinschaft medikamentoese Tumortherapie 45
Early research (Phase 1)Active Not RecruitingNCT01044069
What this trial is testing

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Who this might be right for
LeukemiaAcute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center 93
Testing effectiveness (Phase 2)Study completedNCT05844956
What this trial is testing

DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

Who this might be right for
Lymphoma, Non-Hodgkin
Dizal Pharmaceuticals 17
Testing effectiveness (Phase 2)Study completedNCT03364231
What this trial is testing

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Marginal Zone LymphomaWaldenstrom MacroglobulinemiaNon Follicular Indolent Non-Hodgkin Lymphoma
TG Therapeutics, Inc. 21
Early research (Phase 1)WithdrawnNCT02875002
What this trial is testing

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Who this might be right for
Relapsed and Refractory Aggressive B- and T-cell LymphomasLymphoma
Yale University
Testing effectiveness (Phase 2)Active Not RecruitingNCT05734495
What this trial is testing

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Who this might be right for
Waldenstrom Macroglobulinemia
Dana-Farber Cancer Institute 46
Post-approval studies (Phase 4)WithdrawnNCT05183139
What this trial is testing

In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Takeda
Early research (Phase 1)WithdrawnNCT06411639
What this trial is testing

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

Who this might be right for
Sjogren DiseaseSystemic Lupus Erythematosus
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01082939
What this trial is testing

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center 80
Early research (Phase 1)Study completedNCT04464395
What this trial is testing

Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

Who this might be right for
COVID-19
Corvus Pharmaceuticals, Inc. 30
Large-scale testing (Phase 3)Study completedNCT03366272
What this trial is testing

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

Who this might be right for
Lymphoma, Non-Hodgkin
Universität des Saarlandes 348
Testing effectiveness (Phase 2)Study completedNCT03788291
What this trial is testing

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
University of Rochester 39
Testing effectiveness (Phase 2)Study completedNCT02600897
What this trial is testing

Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 114
Testing effectiveness (Phase 2)Ended earlyNCT00365274
What this trial is testing

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)Study completedNCT00156013
What this trial is testing

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, B-CellLymphoma, Non-Hodgkin
Oncology Specialists, S.C. 33
Not applicableStudy completedNCT00213876
What this trial is testing

Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours

Who this might be right for
Oligodendrogliomas
University Hospital, Strasbourg, France 189
Testing effectiveness (Phase 2)WithdrawnNCT00004040
What this trial is testing

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Who this might be right for
LeukemiaMultiple Myeloma and Plasma Cell Neoplasm
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT01007292
What this trial is testing

YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Who this might be right for
Non-Hodgkin's Lymphoma
Astellas Pharma Inc 43
Next Page